Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Edwin DeJesus

Showing results (61-70 of 154) with videos related to

Pageof 16
Sort By:
Journal of Acquired Immune Deficiency Syndromes (1999)|June 29, 2013
Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of tenofovir alafenamide as 10-day monotherapy in HIV-1-positive adultsPeter J Ruane, Edwin DeJesus, Daniel Berger, et al.
Plos One|May 15, 2014
Simplification to abacavir/lamivudine + atazanavir maintains viral suppression and improves bone and renal biomarkers in ASSURE, a randomized, open label, non-inferiority trialDavid A Wohl, Laveeza Bhatti, Catherine B Small, et al.
AIDS (London, England)|July 2, 2014
Efficacy and safety of maraviroc vs. efavirenz in treatment-naive patients with HIV-1: 5-year findingsDavid A Cooper, Jayvant Heera, Prudence Ive, et al.
HIV Clinical Trials|October 23, 2013
Efficacy and safety 48 weeks after switching from efavirenz to rilpivirine using emtricitabine/tenofovir disoproxil fumarate-based single-tablet regimensAnthony M Mills, Calvin Cohen, Edwin Dejesus, et al.
AIDS (London, England)|January 28, 2006
Pharmacokinetics, pharmacodynamics and safety of once-daily versus twice-daily dosing with enfuvirtide in HIV-infected subjectsMelanie Thompson, Edwin DeJesus, Gary Richmond, et al.
The Journal of Infectious Diseases|January 15, 2004
Antiretroviral activity of the anti-CD4 monoclonal antibody TNX-355 in patients infected with HIV type 1Daniel R Kuritzkes, Jeffrey Jacobson, William G Powderly, et al.
Open Forum Infectious Diseases|March 30, 2022
Long-Term Efficacy, Safety, and Durability of Cabotegravir and Rilpivirine as 2-Drug Oral Maintenance Therapy After 6 Years of StudyKenneth C Sutton, Jerome De Vente, Roger Leblanc, et al.
The Journal of Infectious Diseases|January 13, 2010
Vicriviroc in combination therapy with an optimized regimen for treatment-experienced subjects: 48-week results of the VICTOR-E1 phase 2 trialJamal Suleiman, Barry S Zingman, Ricardo Sobhie Diaz, et al.
AIDS (London, England)|March 18, 2011
Randomized, phase 2 evaluation of two single-tablet regimens elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for the initial treatment of HIV infectionCalvin Cohen, Richard Elion, Peter Ruane, et al.
Plos One|March 4, 2014
HIV-1 transmission patterns in antiretroviral therapy-naïve, HIV-infected North Americans based on phylogenetic analysis by population level and ultra-deep DNA sequencingLisa L Ross, Joseph Horton, Samiul Hasan, et al.
Pageof 16

Showing results (61-70 of 154) with videos related to

Sort By:
Pageof 16
Journal of Acquired Immune Deficiency Syndromes (1999)|June 29, 2013
Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of tenofovir alafenamide as 10-day monotherapy in HIV-1-positive adultsPeter J Ruane, Edwin DeJesus, Daniel Berger, et al.
Plos One|May 15, 2014
Simplification to abacavir/lamivudine + atazanavir maintains viral suppression and improves bone and renal biomarkers in ASSURE, a randomized, open label, non-inferiority trialDavid A Wohl, Laveeza Bhatti, Catherine B Small, et al.
AIDS (London, England)|July 2, 2014
Efficacy and safety of maraviroc vs. efavirenz in treatment-naive patients with HIV-1: 5-year findingsDavid A Cooper, Jayvant Heera, Prudence Ive, et al.
HIV Clinical Trials|October 23, 2013
Efficacy and safety 48 weeks after switching from efavirenz to rilpivirine using emtricitabine/tenofovir disoproxil fumarate-based single-tablet regimensAnthony M Mills, Calvin Cohen, Edwin Dejesus, et al.
AIDS (London, England)|January 28, 2006
Pharmacokinetics, pharmacodynamics and safety of once-daily versus twice-daily dosing with enfuvirtide in HIV-infected subjectsMelanie Thompson, Edwin DeJesus, Gary Richmond, et al.
The Journal of Infectious Diseases|January 15, 2004
Antiretroviral activity of the anti-CD4 monoclonal antibody TNX-355 in patients infected with HIV type 1Daniel R Kuritzkes, Jeffrey Jacobson, William G Powderly, et al.
Open Forum Infectious Diseases|March 30, 2022
Long-Term Efficacy, Safety, and Durability of Cabotegravir and Rilpivirine as 2-Drug Oral Maintenance Therapy After 6 Years of StudyKenneth C Sutton, Jerome De Vente, Roger Leblanc, et al.
The Journal of Infectious Diseases|January 13, 2010
Vicriviroc in combination therapy with an optimized regimen for treatment-experienced subjects: 48-week results of the VICTOR-E1 phase 2 trialJamal Suleiman, Barry S Zingman, Ricardo Sobhie Diaz, et al.
AIDS (London, England)|March 18, 2011
Randomized, phase 2 evaluation of two single-tablet regimens elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for the initial treatment of HIV infectionCalvin Cohen, Richard Elion, Peter Ruane, et al.
Plos One|March 4, 2014
HIV-1 transmission patterns in antiretroviral therapy-naïve, HIV-infected North Americans based on phylogenetic analysis by population level and ultra-deep DNA sequencingLisa L Ross, Joseph Horton, Samiul Hasan, et al.
Pageof 16